Search ⌘K
Tipsheet
An editorial reading of India’s listed companies.
Brief /Earnings / Pharmaceuticals

Shilpa Medicare profit triples to ₹243 cr

Consolidated profits surged behind an improved operating performance and a one-time stake sale, while management targets captive energy savings.

1 earlier story on Shilpa Medicare Ltd.
₹243 cr Consolidated net profit for FY26

What's new

  • Consolidated net profit tripled to ₹243 cr from ₹78.29 cr in FY25.
  • Standalone profit rose to ₹132.97 cr, supported by a 25% revenue increase.
  • Board proposed a final dividend of 60 paise per share.

Why it matters

The jump in bottom-line growth stems partly from a one-time joint venture stake sale, tempering the apparent momentum. While the dividend signals cash-flow confidence, these results largely tracked market expectations set during recent quarterly updates.

What we're watching

  • The integration of the captive renewable power project into operating margins.
  • Shareholder response to the proposed relocation of the registered office to Maharashtra.
  • Sustainability of revenue growth without non-recurring gains.

The full read

Shilpa Medicare wrapped up FY26 with a massive expansion in consolidated net profit, which hit ₹243.33 crore against ₹78.29 crore the year prior. Revenue from operations climbed 20% to reach ₹1,539 crore. The standalone business contributed ₹132.97 crore to that bottom line, nearly doubling from its ₹67.89 crore result in FY25. Much of the consolidated gain relies on a one-time windfall from a joint venture stake sale, and the market had largely priced these numbers in during previous calls. Management is now pivoting toward captive power costs by picking up a 28% stake in a renewable energy firm for ₹4.44 crore. They are also clearing the decks to move the registered office from Karnataka to Maharashtra. The results are solid, but the next phase for the company depends on core performance rather than the asset-divestment boost that defined this year’s earnings.

Mentioned: Shilpa Medicare · FY26 audited results
Primary source BSE filings for SHILPAMED NSE filings for SHILPAMED Research SHILPAMED on Tijori Finance Our reading is derived from the exchange filing. Verify on the exchange before acting.